Abstracts tagged "Epidemiology"

Abstract Number: 0667 • ACR Convergence 2023
The Risk of Stroke and Myocardial Infarction in Systemic Sclerosis: A Population-based Study
Jiwon Hwang¹, Yeonghee Eun², Kyungdo Han³ and Joong Kyong Ahn², ¹Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea, ²Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Department of Statistics and Actuarial Science, Soongsil University, Seoul, South Korea
Background/Purpose: Previous studies have suggested a link between systemic sclerosis (SSc) and cardiovascular disease, but large-scale data are still lacking due to the nature of…
Abstract Number: 0975 • ACR Convergence 2023
Association of HLA-DRB1 Alleles with Ischemic Events and Mortality in a Multi-ethnic Community-living Population
Manmeet Kaur¹, Ronit Katz², Michael H. Criqui¹, Maripat Corr¹, Wendy S. Post³, Matthew Budoff⁴, Gerald P. Morris⁵ and Jan Hughes-Austin⁵, ¹University of California San Diego, San Diego, CA, ²University of Washington, Seattle, WA, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of California Los Angeles, Los Angeles, CA, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Human leukocyte antigen (HLA) DRB1 alleles with specific common amino acids referred to as "the shared epitope (SE)", have been linked to cardiovascular mortality…
Abstract Number: 1174 • ACR Convergence 2023
Anti-HMGCR Immune-mediated Necrotising Myopathy: Calculation of Incidence and Confirmation of Low Malignancy Risk in Two Independent Cohorts. a Retrospective Case Review
Thomas Khoo¹, Xia Lyu², James Lilleker¹, Janine Lamb¹, Vidya Limaye³ and Hector Chinoy⁴, ¹University of Manchester, Manchester, United Kingdom, ²Department of Rheumatology, Shanghai Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China, ³Royal Adelaide Hospital, Adelaide, Australia, ⁴The University of Manchester, Sale, United Kingdom
Background/Purpose: Immune-mediated necrotising myopathy (IMNM) is a rare complication of statin therapy, associated with the development of anti-HMGCR antibodies directed against the enzymatic target of…
Abstract Number: 1653 • ACR Convergence 2023
Up or Down: Does Direction of Stair Climbing Difficulty Matter for Incident Functional Limitation and Knee Replacement in Knee Osteoarthritis?
Jason Jakiela¹, Thomas Bye¹, Sydney Liles² and Daniel White¹, ¹University of Delaware, Newark, DE, ²University of Delaware, Elkton, MD
Background/Purpose: Knee osteoarthritis (OA) is a leading cause of functional limitation (FL) in older adults, with difficulty climbing stairs often the first-reported limitation. Overall increased…
Abstract Number: 1825 • ACR Convergence 2023
Exploring the Health and Cannabis Use Among Young and Middle-Aged Adults with Rheumatologic Conditions in Alberta, Canada
Elaine Yacyshyn, Simran Gulati, Samuel Lowe, Allyson Jones, Tarek Turk, Shelby Yamamoto, Kali Gregg, Linda Kolewaski, Joanne Olson, Pauline Paul and Cheryl Sadowski, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Interest in using cannabis for the management of pain and associated symptoms of rheumatic diseases is rapidly rising in young adults. This, in turn,…
Abstract Number: 2215 • ACR Convergence 2023
Can Axial Spondyloarthritis Unequivocally Be Diagnosed by Rheumatologists in Patients with Chronic Back Pain of Less Than Two Years Duration? The Primary Outcome of the Two-year SPondyloArthritis Caught Early (SPACE) Cohort
Mary Lucy marques¹, Sofia Ramiro², Miranda Van Lunteren³, Rosalinde Stal³, Robert BM Landewé⁴, Marleen van de Sande⁵, Karen Minde Fagerli⁶, Inger Jorid Berg⁶, Maikel van oosterhout⁷, Sofia Exarchou⁸, Roberta Ramonda⁹, Désirée van der Heijde² and Floris Van Gaalen³, ¹Leiden University Medical Center; Centro Hospitalar e Universitário de Coimbra (Department of Rheumatology), Coimbra, Portugal, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ⁴Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Herleen, Netherlands, ⁵Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ⁶Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁷Groene Hart Ziekenhuis, Gouda, Netherlands, ⁸Lund University, Åkarp, Sweden, ⁹University of Padova, Department of Rheumatology, Padova, Italy
Background/Purpose: Unacceptable diagnostic delay in axial Spondyloarthritis (axSpA) remains an issue. In 2008, the longitudinal SPondyloArthritis Caught Early (SPACE)-cohort started to assess the prevalence of…
Abstract Number: 2449 • ACR Convergence 2023
Cognitive Functioning Among Individuals with Systemic Lupus Erythematosus: A Population-Based Study
Laura Plantinga¹, C. Barrett Bowling², Charmayne Dunlop-Thomas¹, Courtney Hoge¹, Bradley Pearce¹, Cristina Drenkard¹ and S. Sam Lim¹, ¹Emory University, Atlanta, GA, ²Duke University, Durham, NC
Background/Purpose: Studies of objectively measured cognitive dysfunction in SLE are often limited by small sample size, limited generalizability, and lack of diversity. We sought to…
Abstract Number: 0129 • ACR Convergence 2023
Rising Incidence and High Mortality of Systemic Sclerosis: A Population-based Cohort Study (2010-2020)
Anukul Karn¹, Sara Achenbach², Alicia Hinze³, Cynthia Crowson¹ and Ashima Makol², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³Mayo Clinic - Rochester, MN, Rochester, MN
Background/Purpose: Systemic Sclerosis (SSc) is a rare chronic inflammatory disease characterized by immune-mediated dysfunction, vasculopathy and widespread internal organ fibrosis; and the highest case fatality…
Abstract Number: 0381 • ACR Convergence 2023
Disease Burden, Patient Experiences, and Unmet Needs in Refractory Rheumatoid Arthritis: Insights from 20 Years of Real-World Data
Kristin Wipfler¹, Bobby Kwanghoon Han², Sofia Pedro³, Urbano Sbarigia⁴, Federico Zazzetti⁵, Anna Sheahan⁶, Iris Lin⁷, Patti Katz⁸, Evo Alemao⁹ and Kaleb Michaud¹⁰, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Washington, Seattle, WA, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴Janssen Pharmaceutica, Beerse, Belgium, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen, Raleigh, NC, ⁷Janssen, Horsham, PA, ⁸University of California San Francisco, San Rafael, CA, ⁹Janssen Pharmaceuticals, New Hope, PA, ¹⁰University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Despite major advances in RA treatment, a substantial number of patients (estimated at 6-21%1) are refractory to multiple advanced therapies. Well-defined refractory RA (reRA)…
Abstract Number: 0668 • ACR Convergence 2023
Increased Risk of Cancer in Patients with Systemic Sclerosis: A Population-based Study
Jiwon Hwang¹, Yeonghee Eun², Kyungdo Han³ and Joong Kyong Ahn², ¹Division of Rheumatology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon-si, South Korea, ²Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Department of Statistics and Actuarial Science, Soongsil University, Seoul, South Korea
Background/Purpose: Previous studies have shown an association between systemic sclerosis and cancer. However, because the disease is rare, large-scale studies are lacking, especially in Asians.…
Abstract Number: 0977 • ACR Convergence 2023
Prevalence of Arthritis in the United States: National Estimates from a Population-based Study
Sumanth Chandrupatla¹, Kranti Rumalla² and Jasvinder Singh¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Northwestern School of Medicine, Chicago, IL
Background/Purpose: Arthritis is the number 1 cause of disability among U.S. adults and reported to cost > $300 billion in direct and indirect costs in…
Abstract Number: 1186 • ACR Convergence 2023
Presence of Erosions Is Not a Risk Factor for the Development of Knee OA in a Hand OA Population: The Framingham OA Study
Tine Vanhaverbeke¹, Gabriela Rabasa², Ruth Wittoek¹, Ida Kristin Haugen³ and David Felson², ¹Dept. of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium, ²Boston University, Boston, MA, ³Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Osteoarthritis (OA) is a prevalent musculoskeletal disease and can affect multiple joint sites in one patient. Studies have shown an association between hand and…
Abstract Number: 1672 • ACR Convergence 2023
Association of COVID-19 Vaccinations with Flares of Systemic Rheumatic Disease: A Case-Crossover Study
Genna Braverman¹, Medha Barbhaiya², Minerva Nong¹, Vivian Bykerk³, Nathaniel Hupert⁴, Colby Lewis V⁴ and Lisa Mandl², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Department of Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: Fear of flare contributes to COVID-19 vaccine hesitancy in patients with systemic rheumatic diseases (SRD). Accurately ascertaining post-vaccine SRD flares and differentiating them from…
Abstract Number: 1845 • ACR Convergence 2023
Development of a Scoring System for Accurate Lupus Nephritis Case Identification in Real-World Databases
Zara Izadi¹, Alfredo Aguirre¹, Christine Anastasiou¹, Julia Kay¹, Gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California San Francisco, San Francisco, CA, ²UCSF / SFVA, San Francisco, CA, ³University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA
Background/Purpose: Accurate identification of prevalent cases of lupus nephritis (LN) is essential for timely patient monitoring and treatment, advancing research, and informing public health initiatives…
Abstract Number: 2220 • ACR Convergence 2023
Factors Associated with Achieving Remission in Patients with Early Peripheral Spondyloarthritis: 10-Year Results from the German Spondyloarthritis Inception Cohort
Murat Torgutalp¹, Xu Peng¹, Fabian Proft², Valeria Rios Rodriguez¹, Judith Rademacher¹, Mikhail Protopopov¹, Hildrun Haibel¹, Martin Rudwaleit³, Joachim Sieper¹ and Denis Poddubnyy⁴, ¹Charité Universitatsmedizine - Berlin, Berlin, Germany, ²Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ³University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁴Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Depending on leading manifestation, Spondyloarthritis (SpA) is classified as axial (axSpA) or peripheral SpA (pSpA). Achieving of remission/inactive disease is key goal in treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].